{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T22:40:07Z","timestamp":1745188807515,"version":"3.40.4"},"reference-count":105,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/mjt.0b013e31826fc5e5","type":"journal-article","created":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T06:54:03Z","timestamp":1352962443000},"page":"449-464","source":"Crossref","is-referenced-by-count":1,"title":["What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms"],"prefix":"10.1097","volume":"19","author":[{"given":"Jeffrey S.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward S.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210202","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1096\/fj.02-0974bkt","article-title":"New weapons to combat an ancient disease: treating diabetes.","volume":"16","author":"Patlak","year":"2002","journal-title":"FASEB J"},{"key":"R2-12-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2078-7685.197528","article-title":". Discovery, treatment and management of diabetes.","volume":"1","author":"Lasker","year":"2010","journal-title":"J Diabetol"},{"key":"R3-12-20210202","first-page":"446","article-title":"Type 2 diabetes: how far have we come Br J Diabetes Vasc Dis.","volume":"2","author":"Lebovitz","year":"2002","journal-title":""},{"key":"R5-12-20210202","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":". Statement by an American Association of Clinical EndocrinologistsAmerican College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"R6-12-20210202","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":". Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"R7-12-20210202","first-page":"S11","article-title":"Standards of medical care in diabetes-2012.","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"R9-12-20210202","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.2337\/dc09-S318","article-title":"Insulin therapy for type 2 diabetes.","volume":"32","author":"Swinnen","year":"2009","journal-title":"Diabetes Care"},{"key":"R10-12-20210202","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2008.03.022","article-title":"Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.","volume":"121","author":"Rolla","year":"2008","journal-title":"Am J Med"},{"key":"R11-12-20210202","first-page":"441","article-title":"Refining basal insulin therapy: what have we learned in the age of analogues Diabetes Metab Res Rev.","volume":"23","author":"Devries","year":"2007","journal-title":""},{"key":"R14-12-20210202","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1463-1326.2006.00685.x","article-title":". Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.","volume":"9","author":"Klein","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"R15-12-20210202","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00000441-200411000-00007","article-title":". A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study.","volume":"328","author":"Fonseca","year":"2004","journal-title":"Am J Med Sci"},{"key":"R16-12-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1463-1326.2004.00363.x","article-title":". Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.","volume":"7","author":"De Leeuw","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"R17-12-20210202","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3121\/cmr.2008.793","article-title":"Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.","volume":"6","author":"Hartman","year":"2008","journal-title":"Clin Med Res"},{"key":"R18-12-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000149569","article-title":". Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.","volume":"82","author":"Fakhoury","year":"2008","journal-title":"Pharmacology"},{"key":"R20-12-20210202","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":". Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"R21-12-20210202","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1463-1326.2008.00915.x","article-title":". Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.","volume":"11","author":"Liebl","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"R22-12-20210202","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dc07-1122","article-title":". Advancing insulin therapy in type 2 diabetes, previously treated with glargine plus oral agents: prandial premixed (lisproILPS) vs. basalbolus (glarginelispro) therapy.","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"R23-12-20210202","first-page":"12","article-title":"Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes.","volume":"9","author":"Levy","year":"2007","journal-title":"Med Gen Med"},{"key":"R25-12-20210202","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/archinte.168.19.2088","article-title":". National trends in treatment of type 2 diabetes mellitus, 1994-2007.","volume":"168","author":"Alexander","year":"2008","journal-title":"Arch Intern Med"},{"key":"R26-12-20210202","first-page":"321","article-title":"Treating type 2 diabetes: how safe are current therapeutic agents Int J Clin Pract.","volume":"63","author":"Philippe","year":"2009","journal-title":""},{"key":"R27-12-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":". Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"R28-12-20210202","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":". Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 metSU).","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"R29-12-20210202","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","article-title":". Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.","volume":"96","author":"Buse","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-12-20210202","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":". DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"R31-12-20210202","first-page":"335","article-title":". Alpha-glucosidase inhibitors for type 2 diabetes mellitus: a systematic review.","volume":"6","author":"van de Laar","year":"2006","journal-title":"Chin J Evid Based Med"},{"key":"R32-12-20210202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/diaclin.20.4.173","article-title":"Five decades of diabetes patient care: the time of my life.","volume":"20","author":"Krosnick","year":"2002","journal-title":"Clin Diabetes"},{"key":"R33-12-20210202","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2337\/diacare.29.03.06.dc05-1937","article-title":". Treatment escalation and rise in HbA1c following successful initial metformin therapy.","volume":"29","author":"Nichols","year":"2006","journal-title":"Diabetes Care"},{"key":"R34-12-20210202","first-page":"845","article-title":"Treatment of diabetes mellitus: general goals, and clinical practice management.","volume":"55","author":"Simo","year":"2002","journal-title":"Rev Esp Cardiol"},{"key":"R35-12-20210202","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"R36-12-20210202","first-page":"789","article-title":". A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II. Mortality results.","volume":"19","author":"Meinert","year":"1970","journal-title":"Diabetes"},{"key":"R37-12-20210202","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc06-1789","article-title":". A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.","volume":"30","author":"Gangji","year":"2007","journal-title":"Diabetes Care"},{"key":"R38-12-20210202","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","article-title":". Is the ADAEASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion A critical analysis.","volume":"53","author":"Schernthaner","year":"2010","journal-title":"Diabetologia"},{"key":"R39-12-20210202","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2337\/dc08-0137","article-title":"Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study.","volume":"31","author":"Charlton","year":"2008","journal-title":"Diabetes Care"},{"key":"R40-12-20210202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.310.6972.83","article-title":"United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.","volume":"310","year":"1995","journal-title":"BMJ"},{"key":"R41-12-20210202","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.3390\/ph3093005","article-title":". Oral hypoglycemic drugs: pathophysiologic basis of their mechanism of action.","volume":"3","author":"Lorenzati","year":"2010","journal-title":"Pharmaceuticals"},{"key":"R42-12-20210202","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2337\/diacare.27.7.1791","article-title":"The phantom of lactic acidosis due to metformin in patients with diabetes.","volume":"27","author":"Misbin","year":"2004","journal-title":"Diabetes Care"},{"key":"R44-12-20210202","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R45-12-20210202","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":". 10-Year follow-up of intensive glucose control in type 2 diabetes.","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"R46-12-20210202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2337\/diacare.22.1.33","article-title":"Efficacy of metformin in the treatment of NIDDM. Meta-analysis.","volume":"22","author":"Johansen","year":"1999","journal-title":"Diabetes Care"},{"key":"R47-12-20210202","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.2337\/dc08-0167","article-title":". Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality: a meta-analysis of observational studies.","volume":"31","author":"Rao","year":"2008","journal-title":"Diabetes Care"},{"key":"R48-12-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157016307781115476","article-title":"Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus.","volume":"4","author":"Modi","year":"2007","journal-title":"Curr Drug Discov Technol"},{"key":"R49-12-20210202","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/diaclin.22.4.162","article-title":"Effects of glycemic control on diabetes complications and on the prevention of diabetes.","volume":"22","author":"Skyler","year":"2004","journal-title":"Clin Diabetes"},{"key":"R50-12-20210202","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":". Effect of nateglinide on the incidence of diabetes and cardiovascular events.","volume":"362","author":"Holman","year":"2010","journal-title":"N Engl J Med"},{"key":"R51-12-20210202","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":". Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.","volume":"32","author":"Schramm","year":"2011","journal-title":"Eur Heart J"},{"key":"R52-12-20210202","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/01.CIR.0000134501.57864.66","article-title":". Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.","volume":"110","author":"Esposito","year":"2004","journal-title":"Circulation"},{"key":"R57-12-20210202","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":". Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"R59-12-20210202","first-page":"166","article-title":"Thiazolidinedione derivatives in type 2 diabetes mellitus.","volume":"64","author":"Tack","year":"2006","journal-title":"Neth J Med"},{"key":"R60-12-20210202","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":". Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.","volume":"368","author":"Gerstein","year":"2006","journal-title":"Lancet"},{"key":"R61-12-20210202","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":". Pioglitazone for diabetes prevention in impaired glucose tolerance.","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"R63-12-20210202","first-page":"1533","article-title":"Diabetes and insulin resistance associated disorders: disease and the therapy.","volume":"83","author":"Chakrabarti","year":"2002","journal-title":"Curr Sci"},{"key":"R64-12-20210202","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","article-title":". Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.","volume":"25","author":"Hanefeld","year":"2004","journal-title":"Eur Heart J"},{"key":"R65-12-20210202","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":". Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"R66-12-20210202","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":". Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"R67-12-20210202","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":". Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"R68-12-20210202","doi-asserted-by":"crossref","first-page":"E443","DOI":"10.1152\/ajpendo.2001.280.3.E443","article-title":". Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas.","volume":"280","author":"Silvestre","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R69-12-20210202","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2011.581663","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction.","volume":"12","author":"Younk","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R70-12-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2337\/diaclin.20.3.137","article-title":"Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy.","volume":"20","author":"Buse","year":"2002","journal-title":"Clin Diabetes"},{"key":"R71-12-20210202","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diab.40.12.1615","article-title":". Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes.","volume":"40","author":"Ludvik","year":"1991","journal-title":"Diabetes"},{"key":"R73-12-20210202","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":". Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"R74-12-20210202","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc09-0395","article-title":". Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.","volume":"32","author":"Riddle","year":"2009","journal-title":"Diabetes Care"},{"key":"R75-12-20210202","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":". Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"R76-12-20210202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/MAJ.0b013e31823ea4af","article-title":"Evolving treatment strategies for the management of type 2 diabetes.","volume":"343","author":"Cefalu","year":"2012","journal-title":"Am J Med Sci"},{"key":"R77-12-20210202","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes.","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"R78-12-20210202","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/1381612013397401","article-title":"Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.","volume":"7","author":"Drucker","year":"2001","journal-title":"Curr Pharm Des"},{"key":"R79-12-20210202","first-page":"18","article-title":"Potential role of oral DPP-4 inhibitors in the ADAEASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents.","volume":"12-","author":"Barnett","year":"2007","journal-title":"Int J Clin Pract Suppl"},{"key":"R80-12-20210202","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1185\/030079906X167336","article-title":"Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.","volume":"23","author":"Meece","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"R81-12-20210202","first-page":"93","article-title":"3rd.","volume":"12","author":"Gavin","year":"2006","journal-title":"How can we implement current therapies and interventions to achieve glycemic control Endocr Pract"},{"key":"R82-12-20210202","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP.","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"R84-12-20210202","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/0145721705285638","article-title":"Dispelling myths and removing barriers about insulin in type 2 diabetes.","volume":"32","author":"Meece","year":"2006","journal-title":"Diabetes Educ"},{"key":"R85-12-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1900\/RDS.2008.5.73","article-title":"Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors.","volume":"5","author":"Pratley","year":"2008","journal-title":"Rev Diabet Stud"},{"key":"R86-12-20210202","first-page":"S187","article-title":"Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.","volume":"16","author":"Garber","year":"2010","journal-title":"Am J Manag Care"},{"key":"R87-12-20210202","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1517\/14728220903241633","article-title":". Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.","volume":"18","author":"Rizzo","year":"2009","journal-title":"Expert Opin Invest Drugs"},{"key":"R88-12-20210202","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":". Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"R89-12-20210202","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":". Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study.","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"R90-12-20210202","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":". Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"R91-12-20210202","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":". Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"R92-12-20210202","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc09-2260","article-title":". Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"R93-12-20210202","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":". One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial.","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"key":"R94-12-20210202","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":". Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"R95-12-20210202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","article-title":". One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.","volume":"65","author":"Pratley","year":"2011","journal-title":"Int J Clin Pract"},{"key":"R97-12-20210202","first-page":"23","article-title":"Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.","volume":"5","author":"Kulasa","year":"2010","journal-title":"Core Evid"},{"key":"R98-12-20210202","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/11207400-000000000-00000","article-title":"Linagliptin: in type 2 diabetes mellitus.","volume":"71","author":"Scott","year":"2011","journal-title":"Drugs"},{"key":"R99-12-20210202","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":". Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.","volume":"48","author":"Mistry","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R100-12-20210202","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":". Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"key":"R102-12-20210202","first-page":"683","article-title":". Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.","volume":"5","author":"Khoo","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"R103-12-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":". Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"R104-12-20210202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1464-5491.2011.03301.x","article-title":". DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.","volume":"28","author":"Wysham","year":"2011","journal-title":"Diabet Med"},{"key":"R105-12-20210202","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":". Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"R106-12-20210202","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":". Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"R108-12-20210202","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":". Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R109-12-20210202","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1900\/RDS.2011.8.348","article-title":"SGLT-2 inhibitors in development for type 2 diabetes treatment.","volume":"8","author":"Bhartia","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"R110-12-20210202","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":". A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"R111-12-20210202","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":". Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"R112-12-20210202","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":". Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"R113-12-20210202","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":". Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial.","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R114-12-20210202","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":". Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R115-12-20210202","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(10)62305-7","article-title":". Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.","volume":"377","author":"Zinman","year":"2011","journal-title":"Lancet"},{"key":"R116-12-20210202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/187221412799015326","article-title":"Degludec: a novel basal insulin.","volume":"6","author":"Kalra","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"R120-12-20210202","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","article-title":". Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.","volume":"35","author":"DeVries","year":"2012","journal-title":"Diabetes Care"},{"key":"R121-12-20210202","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"R122-12-20210202","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann Intern Med"},{"key":"R123-12-20210202","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":". A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"key":"R124-12-20210202","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"R125-12-20210202","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1089\/dia.2010.0239","article-title":"Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts.","volume":"13","author":"Monnier","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"R126-12-20210202","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.diabres.2012.01.027","article-title":"Emerging diabetes therapies and technologies.","volume":"97","author":"Moser","year":"2012","journal-title":"Diabetes Res Clin Pract"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31826fc5e5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T22:24:40Z","timestamp":1745187880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201211000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31826fc5e5","relation":{},"ISSN":["1075-2765"],"issn-type":[{"type":"print","value":"1075-2765"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}